These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 33588260)

  • 41. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ramelteon.
    McGechan A; Wellington K
    CNS Drugs; 2005; 19(12):1057-65; discussion 1066-7. PubMed ID: 16332146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications.
    Herring WJ; Roth T; Krystal AD; Michelson D
    J Sleep Res; 2019 Apr; 28(2):e12782. PubMed ID: 30338596
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders.
    Okino K; Suzuki H; Kondo S; Tomioka H; Tokumasu T; Yamada H; Iwanami A; Inamoto A
    Psychogeriatrics; 2022 Sep; 22(5):595-604. PubMed ID: 35689366
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Suvorexant: a novel therapy for the treatment of insomnia.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suvorexant: something new for sleep?
    Reddy A; Puvvada SC; Kommisetti S; El-Mallakh RS; Lippmann S
    Acta Neuropsychiatr; 2015 Feb; 27(1):53-5. PubMed ID: 25397996
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Suvorexant for the treatment of insomnia.
    Jacobson LH; Callander GE; Hoyer D
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):711-30. PubMed ID: 25318834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effects of ramelteon on a patient with circadian rhythm sleep disorder and mood disorder].
    Yoshihara S; Yoshizawa M; Shirata A; Matsuda M; Tamashiro M; Saito I; Sakamoto K; Fujimura Y; Tamura Y; Chiba S
    Seishin Shinkeigaku Zasshi; 2014; 116(9):746-51. PubMed ID: 25711117
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of ramelteon 8 mg on objective sleep latency in adults with chronic insomnia on nights 1 and 2: pooled analysis.
    Wang-Weigand S; McCue M; Ogrinc F; Mini L
    Curr Med Res Opin; 2009 May; 25(5):1209-13. PubMed ID: 19327100
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of Hypnotic Drug Use with Fall Incidents in Hospitalized Elderly Patients: A Case-Crossover Study.
    Torii H; Ando M; Tomita H; Kobaru T; Tanaka M; Fujimoto K; Shimizu R; Ikesue H; Okusada S; Hashida T; Kume N
    Biol Pharm Bull; 2020; 43(6):925-931. PubMed ID: 32475914
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Herring WJ; Ceesay P; Snyder E; Bliwise D; Budd K; Hutzelmann J; Stevens J; Lines C; Michelson D
    Alzheimers Dement; 2020 Mar; 16(3):541-551. PubMed ID: 31944580
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [New hypnotics ramelteon for the treatment of insomniacs with circadian rhythm disturbance].
    Mishima K
    Nihon Rinsho; 2012 Jun; 70(6):1069-78. PubMed ID: 22690618
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal.
    Sanchez-Alavez M; Benedict J; Wills DN; Ehlers CL
    Sleep; 2019 Apr; 42(4):. PubMed ID: 30715515
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data.
    Snyder E; Ma J; Svetnik V; Connor KM; Lines C; Michelson D; Herring WJ
    Sleep Med; 2016 Mar; 19():93-100. PubMed ID: 27198953
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
    Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ramelteon: a novel approach in the treatment of insomnia.
    Reynoldson JN; Elliott E; Nelson LA
    Ann Pharmacother; 2008 Sep; 42(9):1262-71. PubMed ID: 18648020
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.
    Vermeeren A; Vets E; Vuurman EF; Van Oers AC; Jongen S; Laethem T; Heirman I; Bautmans A; Palcza J; Li X; Troyer MD; Wrishko R; McCrea J; Sun H
    Psychopharmacology (Berl); 2016 Sep; 233(18):3341-51. PubMed ID: 27424295
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts.
    Petrous J; Furmaga K
    BMJ Case Rep; 2017 Oct; 2017():. PubMed ID: 29066641
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Treatment with ramelteon for sleep disturbance in severely disabled children and young adults].
    Miyamoto A; Fukuda I; Tanaka H; Oka R; Araki A; Cho K
    No To Hattatsu; 2013 Nov; 45(6):440-4. PubMed ID: 24313003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.